Skip to content
Independent analysis of NHS open data
PharmaInsight

Aflibercept 6.6mg/165microlitres solution for injection pre-filled syringes

Secondary Care Medicines Data (SCMD) · indicative cost
Data updated April 2026

NHS hospitals in England used £82,490,746 of indicative cost of Aflibercept 6.6mg/165microlitres solution for injection pre-filled syringes in the 12 months to April 2026, about 0.3% of all hospital medicines spend. That is up 0.0% on the previous 12 months.

£82,490,746 0%

Indicative cost · 12 months

18,533,460units

Quantity (VMP units) · 12 months

0.3%

Share of hospital medicines spend

Figure 1. Aflibercept 6.6mg/165microlitres solution for injection pre-filled syringes: NHS hospital indicative cost by month (£ millions)

£0m £11.3m £22.5m Nov 2025 Dec 2025 Jan 2026 Feb 2026 Mar 2026 Apr 2026 £22.5m Nov 2025: £0.6m Dec 2025: £7.1m Jan 2026: £13.1m Feb 2026: £17.7m Mar 2026: £21.6m Apr 2026: £22.5m

Source: NHSBSA Secondary Care Medicines Data, to April 2026

Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.

NHS trusts using Aflibercept 6.6mg/165microlitres solution for injection pre-filled syringes most

By indicative cost over the 12 months to April 2026.

NHS trusts using Aflibercept 6.6mg/165microlitres solution for injection pre-filled syringes most, by indicative cost
NHS trustIndicative cost (12 months)
Western Sussex Hospitals Nhs Found Trust £4,670,050
The Newcastle Upon Tyne Hpl Nhs Found Tr £3,928,306
Moorfields Eye Hospital Nhs Ft £3,414,226
Univ Hpls Bristol Nhs Foundation Trust £3,394,397
University Hospitals Dorset Nhs Ft £2,881,786
Ashford & St Peter's Hospitals Nhs Ft £2,558,650
Univ Hpl B/Ham Nhs Foundation Trust £2,481,538
York Teaching Hospital Nhs Ft £2,389,003
Oxford University Hospitals Nhs Ft £2,332,454
East Kent Hospitals University Nhs Ft £2,220,091

The primary-care picture

No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.